Topical Agents to Remain Most Widely Used Product Type for Treatment of Radiodermatitis

The global radiodermatitis market is consolidated, with the top five players accounting for a share of just over 47% in 2015. These are 3M Healthcare, Smith & Nephew plc, Molnlycke Health Care, Acelity, and Convatec, Inc. Transparency Market Research finds that success in the radiodermatitis market is dependent on the ability of pharma and medical device companies to develop innovative products that can address unmet consumer needs and also help differentiate the company from its competitors.

Stratpharma AG, for instance, launched the StrateXRT in 2016 – a class 1 wound dressing listed with the US FDA and a medical device registered with the European CE mark. This novel and flexible wound dressing is designed for the prevention as well as treatment of radiation dermatitis.

Get Report Sample @

The opportunity in the global radiodermatitis market was worth US$299.6 mn in 2015 and, registering a CAGR of 3.9% from 2016 to 2024, will be worth US$421.5 mn by 2024.

Multichannel Distribution an Effective Approach in Radiodermatitis Market

Topical agents are the most preferred and prescribed products in the radiodermatitis market. Accounting for a share of just under 70% in 2015, the revenue generated by this segment is projected to cross US$300 mn by 2024. The topical segment is anticipated to register a 4.2% CAGR during the forecast period, higher than any other product segment. The oral medication segment holds a negligible share in the global radiodermatitis market and is anticipated to further lose market share by 2024.

By distribution channel, the retail pharmacy store segment led the radiodermatitis market in 2015, closely followed by the online store segment. TMR finds that on the whole, a multichannel approach works increasingly well in the radiodermatitis market owing to the nature of the onset of radiodermatitis, which can occur either during or after radiation therapy.

Geographically, Asia Pacific led the global radiodermatitis market in 2015, accounting for a share of over 45% that year. This region, along with Latin America, are both anticipated to register a CAGR of 4.0% from 2016 to 2024, emerging as two of the most lucrative markets for radiodermatitis treatment.

Innovation in Product Offerings a Key Growth Driver for Radiodermatitis Market

The World Health Organization states that the number of new cancer cases worldwide is projected to rise from 14 million per year in 2012 to 22 million by 2032. Cancer patients are more likely to develop radiation-induced dermatitis owing to frequent radiation treatments. “Unhealthy lifestyle factors, such as obesity and smoking, aggravate the rate of cancer incidence and this will further boost the prevalence as well as market for radiodermatitis,” the author of the study finds.

The global market for radiodermatitis is also fueled by the rising innovation in product offerings. “Companies have been increasingly focused on churning out innovative products in order to fill the gap of unmet needs in the radiodermatitis market,” the lead analyst observes. The painful condition of the patient and poor quality of life has been compelling patients to opt for as many new and different radiodermatitis treatment options as possible and this acts as a driving factor for drug and device manufacturing companies.

View Report @

Relentless R&D Activities Focus on Developing Universally-acceptable Modalities in Radiodermatitis Treatment

Radiodermatitis, commonly known as radiation-induced skin reactions, is an acute side effect that popularly occurs in cancer patients at some point during their radiation therapy. Alternatively, chronic radiodermatitis may surface post-treatment after several months or years.  The acute reactions are a common phenomenon among cancer patients undergoing some sort of radiation therapy. In addition, in a small number of populations affected, these skin reactions are caused by nuclear radiations.

Get Report Sample @

Although, in most cases, the conditions may subside over time, late-onset radiodermatitis is a cause of marked morbidity in patient populations. It not only affects the efficacy of subsequent therapeutic modalities used by clinicians but also have significant repercussions on the quality of life.

Which trends underpin substantial prospects in radiodermatitis treatment?

While the treatment modalities and therapies focused on reducing radiodermatitis reactions are still emerging, radiation therapies used on cancer patients are also undergoing substantial advances. Some of the major products used in the treatment are topical products including antibiotics, corticosteroid creams, and hydrophilic creams. The rising prevalence of various cancer types and relentless industry efforts to bring innovation in technologies to control the underlying symptoms and manage acute or chronic radiodermatitis. Companies are also tapping into avenues in emerging markets characterized by vast unmet medical needs.

With ample opportunities in the offing, the global radiodermatitis market is projected to touch a valuation of US$421.5 by 2024 end, garnering a CAGR of 3.90% in between the period from 2016 to 2024, according to estimates by Transparency Market Research.

A number of clinical trials are being conducted in developed nations, notably in U.S., for evaluating the potential of low-level laser therapy on treating radiodermatitis. These are focused on developing universally-acceptable evidence-based treatment modality for cancer patients suffering from acute radiodermatitis, particularly in head and neck region. Such studies play a key role in driving the current trajectory of research activities in the market.

Which are the regions expected to present significant promising avenues, contributing attractive revenues to global market?

Europe as well as North America are robust regional markets for radiodermatitis. The growth is broadly driven by incessant research and development activities, a spate of innovative product launches in recent years, and substantial, constant support by government institutes. Furthermore, the presence of a copious number of prominent pharmaceutical companies is aiding in the substantial expansion.

On the other hand, Asia Pacific is home to ample promising opportunities for market players. A notably swelling patient populations in several of its key economies, coupled with the rising incidence of acute radiodermatitis conditions, contribute to a burgeoning demand for treatments.

View Report @